| Literature DB >> 25436518 |
Steffen Gaali1, Alexander Kirschner1, Serena Cuboni1, Jakob Hartmann2, Christian Kozany1, Georgia Balsevich2, Christian Namendorf1, Paula Fernandez-Vizarra2, Claudia Sippel1, Anthony S Zannas3, Rika Draenert4, Elisabeth B Binder5, Osborne F X Almeida2, Gerd Rühter6, Manfred Uhr1, Mathias V Schmidt2, Chadi Touma2, Andreas Bracher7, Felix Hausch1.
Abstract
The FK506-binding protein 51 (FKBP51, encoded by the FKBP5 gene) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the structurally similar but functional opposing homolog FKBP52, and all known FKBP ligands are unselective. Here, we report the discovery of the potent and highly selective inhibitors of FKBP51, SAFit1 and SAFit2. This new class of ligands achieves selectivity for FKBP51 by an induced-fit mechanism that is much less favorable for FKBP52. By using these ligands, we demonstrate that selective inhibition of FKBP51 enhances neurite elongation in neuronal cultures and improves neuroendocrine feedback and stress-coping behavior in mice. Our findings provide the structural and functional basis for the development of mechanistically new antidepressants.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25436518 DOI: 10.1038/nchembio.1699
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040